[breadcrumb_custom]

Buy, Sell Or Hold Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) At $39.64?

In last trading session, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) saw 0.47 million shares changing hands with its beta currently measuring 2.64. Company’s recent per share price level of $39.64 trading at $1.73 or 4.56% at ring of the bell on the day assigns it a market valuation of $1.06B. That closing price of ARCT’s stock is at a premium of 1.61% from its 52-week high price of $39.00 and is indicating a premium of 64.15% from its 52-week low price of $14.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.34 million shares which gives us an average trading volume of 424.61K if we extend that period to 3-months.

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information

Upright in the green during last session for gaining 4.56%, in the last five days ARCT remained trading in the green while hitting it’s week-highest on Friday, 02/09/24 when the stock touched $39.64 price level, adding 0.6% to its value on the day. Arcturus Therapeutics Holdings Inc’s shares saw a change of 25.72% in year-to-date performance and have moved 14.17% in past 5-day. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) showed a performance of 15.91% in past 30-days. Number of shares sold short was 4.15 million shares which calculate 10.07 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Arcturus Therapeutics Holdings Inc (ARCT) estimates and forecasts

Statistics highlight that Arcturus Therapeutics Holdings Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 35.29% of value to its shares in past 6 months, showing an annual growth rate of -640.00% while that of industry is 15.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

ARCT Dividends

Arcturus Therapeutics Holdings Inc is more likely to be releasing its next quarterly report between March 26 and April 01 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s Major holders

Insiders are in possession of 8.91% of company’s total shares while institution are holding 92.65 percent of that, with stock having share float percentage of 101.71%. Investors also watch the number of corporate investors in a company very closely, which is 92.65% institutions for Arcturus Therapeutics Holdings Inc that are currently holding shares of the company. Federated Hermes, Inc. is the top institutional holder at ARCT for having 4.78 million shares of worth $137.05 million. And as of Jun 29, 2023, it was holding 17.97% of the company’s outstanding shares.

The second largest institutional holder is Blackrock Inc., which was holding about 1.99 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 7.49% of outstanding shares, having a total worth of $57.14 million.

On the other hand, Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund are the top two Mutual Funds which own company’s shares. As of Jul 30, 2023, the former fund manager was holding 2.48 million shares of worth $86.53 million or 9.31% of the total outstanding shares. The later fund manager was in possession of 2.23 million shares on Jul 30, 2023, making its stake of worth around $77.96 million in the company or a holder of 8.38% of company’s stock.

On Key

Related Posts